Clinical data | |
---|---|
Trade names | Prepulsid, Propulsid |
AHFS/Drugs.com | FDA Professional Drug Information |
MedlinePlus | a694006 |
Pregnancy category |
|
Routes of administration | By mouth (tablets), suspension |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 30-40% |
Protein binding | 97.5% |
Metabolism | liver CYP3A4, intestinal |
Elimination half-life | 10 hours |
Excretion | kidney, bile duct |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.072.423 |
Chemical and physical data | |
Formula | C23H29ClFN3O4 |
Molar mass | 465.95 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Cisapride is a gastroprokinetic agent, a drug that increases motility in the upper gastrointestinal tract. It acts directly as a serotonin 5-HT4 receptor agonist and indirectly as a parasympathomimetic. Stimulation of the serotonin receptors increases acetylcholine release in the enteric nervous system. It has been sold under the trade names Prepulsid (Janssen-Ortho) and Propulsid (in the United States). It was discovered by Janssen Pharmaceuticals in 1980. In many countries, it has been either withdrawn from the market or had its indications limited due to incidence of serious cardiac side-effects.[2] Propulsid was linked to children's deaths.[3]
The commercial preparations of this drug are the racemic mixture of both enantiomers of the compound. The (+) enantiomer itself has the major pharmacologic effects and does not induce many of the detrimental side-effects of the mixture.[4]